# US Biopharmaceuticals Market

> US Biopharmaceuticals Market Research Report By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End-use (Hospitals, Biotechnology Companies, Pharmaceutical Companies), and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.21%
- **2024:** $ 92.1 Billion
- **2025:** $ 95.98 Billion
- **2035:** $ 145 Billion
- **Key Players:** Companies such AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Gilead Sciences (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Roche (CH), Sanofi (FR), Takeda Pharmaceutical (JP) are some of the major participants in the global market.

**Report ID:** MRFR/MED/49630-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 30, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biopharmaceuticals-market-51388

---

## Market Summary

## **US Biopharmaceuticals Market Overview**

As per MRFR analysis, the US Biopharmaceuticals Market Size was estimated at 70.43 (USD Billion) in 2023. The US Biopharmaceuticals Market is expected to grow from 73.5 (USD Billion) in 2024 to 115.5 (USD Billion) by 2035. The US Biopharmaceuticals Market CAGR (growth rate) is expected to be around 4.195% during the forecast period (2025 - 2035).

### **Key US Biopharmaceuticals Market Trends Highlighted**

Technology breakthroughs and the growing need for personalised therapy are driving major trends in the US biopharmaceuticals business right now. One major factor has been the increase in chronic illnesses, which calls for novel therapies, which biopharmaceuticals frequently offer.

The market is also changing as a result of the push for biologics and biosimilars, with many businesses concentrating on creating these goods to solve issues with cost and efficacy. In addition, US regulatory bodies are expediting biopharmaceutical approval procedures, which incentivises businesses to launch novel medicines as soon as possible.

Expanding R&D expenditures and using modern manufacturing techniques like automation and continuous manufacturing are two opportunities in the US biopharmaceutical sector. It is anticipated that this change will shorten the time it takes for innovative treatments to reach the market and increase production.

Additionally, the increased focus on precision medicine presents unrealised possibilities for customised treatments that address the needs of each patient. A noteworthy trend in recent years has been the cooperation of academic institutions and biopharmaceutical businesses, which reflects a common goal in research and innovation.

In order to turn scientific discoveries into effective treatments, this cooperation is essential. Furthermore, medication research and discovery in the US are starting to be greatly impacted by the rise of digital health technologies like artificial intelligence and big data analytics.

These patterns point to a changing environment where cooperation and cutting-edge technology are essential for the biopharmaceutical industry's continued expansion in the area.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **US Biopharmaceuticals Market Drivers**

### **Rising Demand for Biological Medicine**

The growing prevalence of chronic diseases, such as diabetes and cancer, is driving the demand for biopharmaceutical medicines in the United States. According to the Centers for Disease Control and Prevention (CDC), chronic diseases affect approximately 6 in 10 adults in the US, with diabetes alone affecting over 34 million people.

This increasing patient population boosts the US Biopharmaceuticals Market, as more patients seek effective treatments. Established companies like Amgen and Genentech are actively investing in Research and Development for innovative biological therapies to cater to this rising demand.

With the aging population and increased healthcare access, the market for biopharmaceuticals is poised for significant growth over the next decade.

### **Advancements in Genetic Engineering**

Technological advancements in genetic engineering, particularly in gene therapy and monoclonal antibody production, are propelling the growth of the biopharmaceuticals market in the US. According to the National Institutes of Health (NIH), gene therapy clinical trials have increased significantly in number, with over 2,100 trials initiated since 2015.

Key organizations, such as Novartis and Gilead Sciences, are leveraging these advancements to develop pioneering treatment options, which are not only therapeutically beneficial but also economically viable. This rapid evolution in biopharmaceutical technology fosters innovation, enhancing the overall landscape of the US Biopharmaceuticals Market.

### **Supportive Regulatory Environment**

The regulatory environment in the United States is becoming increasingly supportive of biopharmaceutical innovation. The Food and Drug Administration (FDA) has streamlined approval processes for novel therapies, including the 21st Century Cures Act, which emphasizes faster entry to the market for breakthrough designs.

This supportive framework has led to a notable increase in approvals; in 2020, the FDA approved 53 new medicines, many of which are biopharmaceuticals. Key players such as Pfizer and Merck benefit from this regulatory support, encouraging further investment in the US biopharmaceuticals market. As regulations continue to evolve favorably, it unlocks growth potential for biopharmaceutical products.

### **Increased Investment in Research and Development**

There is a heightened focus on Research and Development (R&D) within the US Biopharmaceuticals Market, with spending exceeding $83 billion in 2020 according to the Pharmaceutical Research and Manufacturers of America (PhRMA).

This robust investment is primarily driven by large pharmaceutical companies such as Johnson & Johnson and Bristol-Myers Squibb, who are prioritizing R&D to innovate and enhance their product pipelines. The increased funding facilitates the discovery of novel therapies targeting complex diseases, further bolstering market growth.

With continuous financial support for research initiatives in the US, the biopharmaceutical sector is positioning itself for exponential advancements and market expansion.

## **US Biopharmaceuticals Market Segment Insights**

### **Biopharmaceuticals Market Product Type Insights**

The US Biopharmaceuticals Market has undergone significant evolution, particularly within the Product Type segmentation, showcasing a diverse range of therapeutic solutions essential for improving patient outcomes and enhancing healthcare delivery.

Among these, Monoclonal Antibodies are a crucial player, accounting for a substantial share of the market due to their precise targeting of disease mechanisms, particularly in oncology and autoimmune disorders. Their significance is underscored by an increasing number of approved therapies that leverage their unique ability to bind specifically to antigens, providing targeted treatment with reduced side effects compared to traditional therapies.

Similarly, Recombinant Proteins represent another major category, utilized in various treatments including hormone deficiencies, hemophilia, and other genetic disorders. The advancement of recombinant DNA technology has enabled the manufacture of these proteins in large quantities, driving their adoption as reliable and effective treatment options for many chronic conditions.

Vaccines have gained unprecedented importance, especially in light of recent global health challenges, leading to a surge in innovation and development within this area. The US has positioned itself at the forefront of vaccine research, illustrating the capacity to rapidly develop and deploy vaccines, an achievement that is crucial not only for public health but also for the overall economy.

Cellular Therapies, which include stem cell therapy and gene editing, are emerging as pivotal therapies that offer groundbreaking potential for treating a range of diseases, including cancer and genetic disorders. Their ability to potentially cure diseases at a cellular level places them on the cusp of transforming the treatment landscape, although they also present unique regulatory challenges and require significant investment in Research and Development.

The collective growth drivers within the Product Type segment stem from advancements in biotechnology, increased R&D funding, and shifting healthcare paradigms focusing on personalized medicine. Moreover, the rising prevalence of chronic diseases, an aging population, and greater acceptance of biopharmaceuticals among healthcare providers and patients alike are fueling market expansion.

Despite the tremendous opportunities, there are challenges, particularly related to high development costs and timeframes associated with bringing new biopharmaceuticals to market. Regulatory requirements and the complex nature of biological products add layers of complexity that necessitate extensive expertise and resources.

Overall, the Product Type segment in the US Biopharmaceuticals Market is characterized by rapid innovation and a strong emphasis on developing therapies that address unmet medical needs, all while grappling with the intricate balance of managing costs and ensuring accessibility.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Biopharmaceuticals Market Application Insights**

The Application segment of the US Biopharmaceuticals Market plays a crucial role in addressing various health challenges faced by the population. This segment encompasses critical areas such as Oncology, Autoimmune Diseases, Infectious Diseases, and Cardiovascular Diseases, which are increasingly prominent due to shifting demographics and lifestyle changes in the US.

Oncology, in particular, is of significant importance as it accounts for a substantial portion of biopharmaceutical research and Development, driven by the rising incidence of cancer. Autoimmune diseases, including conditions like rheumatoid arthritis and lupus, also contribute significantly, as innovative therapies are increasingly being developed due to growing patient populations.

Infectious diseases remain a pivotal focus, particularly in the wake of recent global health crises, emphasizing the need for rapid vaccine and therapeutic development. Lastly, Cardiovascular Diseases are a leading cause of mortality in the US, thus driving ongoing investments in biopharmaceutical solutions to enhance patient outcomes.

The interplay of these areas within the US Biopharmaceuticals Market revenue reflects not just the demand for treatment advancements but also the broader trends of personalized medicine and integrated healthcare solutions, positioning the industry for sustained growth.

In summary, the Application segment encompasses diverse yet interlinked areas vital to improving public health and advancing therapeutic innovation in the US.

### **Biopharmaceuticals Market End-use Insights**

The US Biopharmaceuticals Market, particularly within the End-use segment, showcases diverse applications across various healthcare settings, which significantly contributes to the overall growth and dynamics of the industry.

Hospitals play a crucial role as they require a continuous supply of biopharmaceuticals for treatments, resulting in significant demand and consumption patterns. Biotechnology Companies serve as innovators in this market, focusing on novel therapies and personalized medicine, driving advancements that improve patient outcomes.

Pharmaceutical Companies, meanwhile, leverage their established infrastructure for the development and distribution of biologics, creating synergy with existing offerings. This segmentation highlights the impact of regulatory support and technological innovations, such as gene therapies and monoclonal antibodies, which are reshaping treatment paradigms.

Additionally, the increasing prevalence of chronic diseases and the aging population in the US augment the need for effective biopharmaceutical solutions, creating a thriving environment for growth opportunities.

The US Biopharmaceuticals Market statistics indicate a robust framework where collaboration and investment in Research and Development remain pivotal, responding effectively to evolving healthcare challenges and patient needs.

### **Biopharmaceuticals Market Route of Administration Insights**

The Route of Administration segment plays a critical role in the US Biopharmaceuticals Market, focusing on how therapeutic agents are delivered to patients. Among the various methods, Intravenous (IV) administration is prominent due to its ability to provide immediate drug effects and is often used for critically ill patients who require rapid medication delivery.

Subcutaneous administration has gained traction as a user-friendly alternative for chronic conditions, allowing patients to self-administer medications comfortably at home. Intramuscular administration is also significant, utilized for vaccines and hormonal therapies, as it offers a reliable absorption rate and sustained release of medications.

These administration routes are shaped by market growth drivers such as the increasing prevalence of chronic diseases and patient preference for convenient delivery methods. The US's healthcare infrastructure further supports these administration routes through extensive healthcare networks that facilitate access to biopharmaceuticals.

These factors collectively influence the US Biopharmaceuticals Market data, paving the way for innovations and improvements in drug delivery systems.

## **US Biopharmaceuticals Market Key Players and Competitive Insights**

The US Biopharmaceuticals Market is characterized by a dynamic and competitive landscape driven by innovation, advancements in biotechnology, and a strong regulatory framework. This market is often influenced by various factors such as the increasing prevalence of chronic diseases, a growing geriatric population, and the surge in demand for personalized medicine.

Companies in this sector are constantly striving to enhance their product portfolios through research and development, focusing on unmet medical needs while navigating a complex regulatory environment. Competitive insights reveal that collaboration among industry players, academic institutions, and regulatory bodies is essential in driving further advancements and ensuring that new therapies reach patients efficiently and effectively.

The shift towards biologics and biosimilars has also intensified competition, as firms work to establish their market presence and capture a larger share of the growing biopharmaceutical market in the US.

In terms of market presence, Biogen stands out for its strong focus on neurological diseases, holding a robust portfolio that includes therapies for conditions such as multiple sclerosis and spinal muscular atrophy. The company's research and development capabilities are underscored by a commitment to cutting-edge science, enabling Biogen to maintain a leadership position in specialty therapeutics.

Its established reputation for innovation in the biopharmaceutical sector is further supported by strategic partnerships and collaborations, allowing Biogen to expand its research initiatives and enhance its therapeutic offerings. Additionally, Biogen's investment in new technologies and clinical trials positions it favorably in a competitive market, while its extensive network allows for effective distribution and access to critical markets.

Pfizer has solidified its place within the US Biopharmaceuticals Market through a diverse and comprehensive product portfolio, which encompasses vaccines, small-molecule drugs, and biologics. The company has made substantial gains in areas like oncology, immunology, and rare diseases, bolstered by a strong pipeline of innovative products.

Pfizer’s notable strengths include its extensive research and development infrastructure, which enables rapid advancements, and its expertise in managing complex clinical trials. The company's ability to establish strategic mergers and acquisitions has not only expanded its market presence but also enhanced its technological capabilities and therapeutic offerings.

Products such as vaccines and treatments for major health concerns have led Pfizer to become a household name. Furthermore, its commitment to sustainability and access to medicines demonstrates Pfizer's proactive stance in addressing public health challenges within the US. Through targeted investments and strategic collaborations, Pfizer continues to drive growth and maintain its competitive edge in the biopharmaceutical landscape.

### **Key Companies in the US Biopharmaceuticals Market Include**

### **US Biopharmaceuticals Market Developments**

The US Biopharmaceuticals Market is currently witnessing notable developments, including strong demand for innovation driven by ongoing research and development initiatives among key players such as Biogen, Pfizer, and Moderna, particularly in the fields of oncology and biotechnology.

In September 2023, Gilead Sciences announced a collaboration with another firm to expand its portfolio of CAR-T cell therapies, emphasizing the growing trend of partnerships to enhance drug development capabilities. Moreover, Eli Lilly and Company reported significant growth in revenues attributed to its diabetes and oncology products, indicating a robust market presence.

Recent mergers and acquisitions have shaped the landscape, with AstraZeneca acquiring a smaller biotech firm in August 2023 to enhance its oncology pipeline, alongside Johnson and Johnson's focus on precision medicine through acquisitions. The US government continues to prioritize healthcare accessibility and affordability, impacting pricing strategies within the biopharmaceutical sector.

Notably, in 2022, Bristol Myers Squibb expanded its footprint by acquiring Celgene, emphasizing the trend toward consolidation within the industry. As pharmaceutical companies strive to meet evolving healthcare needs, the market's valuation is projected to continue growing.

## **Biopharmaceuticals Market Segmentation Insights**

### **Biopharmaceuticals Market Product Type Outlook**

### **Biopharmaceuticals Market Application Outlook**

### **Biopharmaceuticals Market End-use Outlook**

### **Biopharmaceuticals Market Route of Administration Outlook**

- Intravenous
- Subcutaneous
- Intramuscular

## Market Drivers

### Enhanced Regulatory Frameworks

The evolving regulatory frameworks in the US are shaping the landscape of the US biopharmaceuticals industry. Regulatory agencies, such as the Food and Drug Administration (FDA), are streamlining approval processes for innovative therapies, thereby expediting patient access to new treatments. Recent initiatives aimed at fostering innovation, such as the Breakthrough Therapy designation, are encouraging companies to invest in the development of novel biopharmaceuticals. 
 
This regulatory support is crucial, as it not only enhances the speed of bringing products to market but also ensures that safety and efficacy standards are maintained. As these frameworks continue to evolve, they are likely to create a more favorable environment for growth in the US market.

### Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders is a significant driver for the US biopharmaceuticals Market. According to the Centers for Disease Control and Prevention (CDC), chronic diseases account for 7 out of 10 deaths in the US, highlighting the urgent need for effective treatment options. 
 
This growing patient population is propelling demand for innovative biopharmaceutical products, which are often more effective than traditional therapies. As a result, the market is expected to expand, with estimates suggesting a growth rate of approximately 8% annually over the next few years. This trend underscores the critical role that biopharmaceuticals play in addressing public health challenges.

### Investment in Research and Development

Investment in research and development (R&D) is a crucial driver of the US biopharmaceuticals Market. Pharmaceutical companies are increasingly allocating substantial resources to R&D to discover and develop new therapies. In 2025, it is anticipated that R&D spending in the biopharmaceutical sector will exceed $200 billion, reflecting a commitment to innovation. 
 
This investment is essential for advancing the understanding of complex diseases and developing targeted therapies. Moreover, collaborations between academic institutions and industry players are fostering a conducive environment for breakthroughs in biopharmaceuticals. As R&D efforts intensify, the market is likely to witness a wave of new product launches, further stimulating growth.

### Technological Advancements in Biopharmaceuticals

The US biopharmaceuticals Market is experiencing a surge in technological advancements, particularly in areas such as gene therapy and monoclonal antibodies. These innovations are enhancing the efficacy and safety of treatments, leading to improved patient outcomes. 
 

- For instance, the market for monoclonal antibodies alone is projected to reach approximately $150 billion by 2025, reflecting a compound annual growth rate (CAGR) of around 10%.

 
Furthermore, advancements in biomanufacturing processes are reducing production costs and time, thereby increasing accessibility to novel therapies. As these technologies continue to evolve, they are likely to drive growth in the US industry, attracting investments and fostering competition among key players.

### Aging Population and Increased Healthcare Expenditure

The aging population in the US is a significant factor influencing the Market. As individuals age, they are more susceptible to various health conditions, leading to increased demand for biopharmaceutical interventions. The US Census Bureau projects that by 2030, approximately 20% of the population will be 65 years or older, which will likely escalate healthcare expenditures. 
 

- In 2025, healthcare spending is expected to reach around $4 trillion, with a substantial portion directed towards biopharmaceuticals. This demographic shift presents both challenges and opportunities for the market, as companies strive to develop therapies that cater to the unique needs of older adults.

## Future Outlook

The US Biopharmaceuticals Industry is projected to grow at a 4.21% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for personalized medicine, and regulatory support.

**New opportunities:**

- Development of biosimilars targeting high-cost biologics Expansion of telehealth services for remote patient monitoring Investment in AI-driven drug discovery platforms

By 2035, the US biopharmaceuticals industry is expected to achieve robust growth and innovation.

## Segment Insights

### By Product Type: Monoclonal Antibodies (Largest) vs. Vaccines (Fastest-Growing)

The US biopharmaceuticals market is characterized by a diverse range of product types, with monoclonal antibodies holding the largest share. This product type dominates due to their effectiveness in treating various diseases, particularly cancer and autoimmune disorders. Following closely are recombinant proteins and cellular therapies, which also play significant roles in the market, contributing to innovative treatment options. Vaccines, while traditionally a smaller segment, are rapidly gaining ground as infectious diseases continue to pose public health challenges. The growth trends in the US market are influenced by several factors. Monoclonal antibodies benefit from ongoing research and development, positioning them as a stable cornerstone in treatment innovation. Conversely, vaccines have experienced a surge in demand, driven by heightened awareness of disease prevention and advancements in technology. Cellular therapies represent an emerging area with potential growth due to their ability to offer personalized treatment solutions, indicating a promising future in biopharmaceutical developments.

Monoclonal Antibodies (Dominant) vs. Vaccines (Emerging)

Monoclonal antibodies are a dominant product type in the US biopharmaceuticals market, recognized for their precision in targeting specific disease pathways and their success in the oncology space. Their established use and approval across multiple indications have led to substantial market penetration and a loyal patient base. In contrast, vaccines are an emerging segment with growing relevance driven by increased public health initiatives and adaptation to new infectious agents. This segment is characterized by innovation in adjuvants and delivery methods, fulfilling an urgent need for effective vaccination solutions. Together, these segments illustrate a dynamic interplay between established therapies and emerging innovations, crucial for addressing both chronic and infectious diseases.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

The US biopharmaceuticals market showcases distinct dynamics within its application segment, where Oncology stands out as the largest area, capturing a significant market share. This dominance is driven by the increasing incidence of cancer, leading to greater investments in research and development of targeted therapies. Autoimmune Diseases and Infectious Diseases also contribute meaningfully, but trail behind Oncology in terms of market share distribution. The growth trends in this segment are markedly influenced by technological advancements, enabling the development of innovative therapies. Infectious Diseases, in particular, are experiencing a surge in interest due to the recent pandemic, positioning it as the fastest-growing segment within the application category. Increased healthcare expenditure and rising awareness of treatment options further underpin the growth of these segments, promising a dynamic landscape in the years ahead.

Oncology: Dominant vs. Autoimmune Diseases: Emerging

Oncology represents the dominant force in the US biopharmaceuticals industry, characterized by a robust pipeline of therapeutics and a vast array of treatment options tailored for various cancer types. This segment benefits from substantial funding and accelerated approval processes, making it appealing for both investors and researchers. Conversely, Autoimmune Diseases, while labeled as emerging, are gaining traction due to a growing patient base and increasing prevalence. Treatments targeting these ailments are becoming more sophisticated, reflecting a shift towards individualized medicine. The comparative positioning highlights a promising future for Autoimmune Diseases, with innovations striving to bridge the gap with the well-established Oncology segment.

### By End-use: Hospitals (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the US biopharmaceuticals market, hospitals hold a significant share as the dominant end-use segment, largely due to their extensive patient base and the requirement for advanced therapies. Biotechnology companies follow closely, leveraging innovative strategies and cutting-edge research to carve their niche, while pharmaceutical companies also play a key role in drug development and commercialization, albeit to a slightly lesser extent. The growth trends in this segment are influenced by an increasing demand for personalized medicine and biologics, with hospitals leading due to their integrated healthcare delivery systems. Biotechnology companies are positioned as the fastest-growing segment, driven by technological advancements and a shift towards biopharmaceuticals for treating chronic diseases. The increasing collaboration among stakeholders is also accelerating progress in this space, offering substantial growth opportunities.

Hospitals (Dominant) vs. Biotechnology Companies (Emerging)

Hospitals are the dominant end-use segment in the US biopharmaceuticals market, primarily due to their vast infrastructure and ability to administer complex therapies directly to patients. This sector benefits from a continuous flow of patients requiring various biopharmaceutical treatments, solidifying its leading position. On the other hand, biotechnology companies are emerging as a crucial segment, utilizing innovative research and development to introduce breakthrough therapies to the market. These companies are heavily focused on biologics and personalized medicine, attracting significant investment and partnerships. The dynamics between these two segments create a competitive landscape, with hospitals relying on biotech innovations to enhance patient care while biotechnology companies strive to meet the evolving needs of healthcare providers.

### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

The market share distribution among the route of administration values reveals that intravenous administration holds the largest share, driven by its efficiency and immediate effects on patients. In contrast, subcutaneous routes are increasingly gaining traction, appealing to both manufacturers and patients for their convenience and ease of self-administration, which contributes to their growing market presence. Growth trends indicate a significant shift towards more patient-centered approaches in the biopharmaceuticals sector. The demand for subcutaneous administration is rising as it allows patients to manage their treatments at home, reducing hospital visits. Additionally, advancements in formulation technologies are expected to enhance the viability of other administration routes, further diversifying the therapeutic options available in the market.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration is recognized as the dominant route in the US biopharmaceuticals market market due to its rapid delivery of medications directly into the bloodstream, ensuring immediate therapeutic effects. This method is particularly favored for acute treatments, including chemotherapy and immunotherapy, where timing is critical. On the other hand, subcutaneous administration is emerging as a favored choice for chronic disease management, appealing to patients seeking more autonomy in their treatment plans. Its ease of use and less invasive nature position it as a strong competitor, especially in the management of conditions like diabetes and rheumatoid arthritis where regular injections are necessary.

## Competitive Benchmarking

The US biopharmaceuticals market in the US is characterized by intense competition and rapid innovation, driven by a combination of technological advancements, increasing healthcare demands, and a growing emphasis on personalized medicine. Major players such as AbbVie (US), Amgen (US), and Gilead Sciences (US) are strategically positioned to leverage their extensive research capabilities and robust product pipelines. 
 
AbbVie (US) focuses on expanding its immunology portfolio, while Amgen (US) emphasizes biomanufacturing efficiency and innovative therapies. Gilead Sciences (US) is increasingly investing in antiviral treatments and oncology, reflecting a broader trend towards specialized therapies. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and therapeutic advancements are paramount.Key business tactics within the market include localized manufacturing and supply chain optimization, which are essential for meeting the diverse needs of patients across different regions.
 
The competitive structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a variety of therapeutic options, yet the influence of major companies remains significant, as they often set the pace for innovation and market trends.
 
In October 2025, AbbVie (US) announced a strategic partnership with a leading technology firm to enhance its drug discovery processes through artificial intelligence. This collaboration is expected to streamline research and development, potentially reducing time-to-market for new therapies. Such initiatives underscore AbbVie's commitment to integrating cutting-edge technology into its operations, thereby enhancing its competitive edge in the biopharmaceutical landscape.
 
In September 2025, Amgen (US) unveiled a new biomanufacturing facility in California, aimed at increasing production capacity for its biologics portfolio. This investment not only signifies Amgen's dedication to meeting growing demand but also reflects a broader industry trend towards enhancing manufacturing capabilities to ensure supply chain reliability. The facility is anticipated to bolster Amgen's position in the market by enabling faster delivery of critical therapies.
 
In August 2025, Gilead Sciences (US) expanded its oncology pipeline through the acquisition of a biotech firm specializing in novel cancer therapies. This acquisition is likely to enhance Gilead's therapeutic offerings and strengthen its market position in oncology, an area of increasing importance within the biopharmaceutical sector. The move illustrates Gilead's proactive approach to expanding its portfolio and addressing unmet medical needs.
 
As of November 2025, current trends in the US market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. The focus on supply chain reliability and the ability to deliver novel therapies will likely become critical factors in maintaining a competitive advantage.

## Recent News & Developments

The US Biopharmaceuticals industry is currently witnessing notable developments, including strong demand for innovation driven by ongoing research and development initiatives among key players such as Biogen, Pfizer, and Moderna, particularly in the fields of oncology and biotechnology.

In September 2023, Gilead Sciences announced a collaboration with another firm to expand its portfolio of CAR-T cell therapies, emphasizing the growing trend of partnerships to enhance drug development capabilities. Moreover, Eli Lilly and Company reported significant growth in revenues attributed to its diabetes and oncology products, indicating a robust market presence.

Recent mergers and acquisitions have shaped the landscape, with AstraZeneca acquiring a smaller biotech firm in August 2023 to enhance its oncology pipeline, alongside Johnson and Johnson's focus on precision medicine through acquisitions. The US government continues to prioritize healthcare accessibility and affordability, impacting pricing strategies within the biopharmaceutical sector.

Notably, in 2022, Bristol Myers Squibb expanded its footprint by acquiring Celgene, emphasizing the trend toward consolidation within the industry. As pharmaceutical companies strive to meet evolving healthcare needs, the market's valuation is projected to continue growing.

## Report Scope

| MARKET SIZE 2024 | 92.1(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 95.98(USD Billion) |
| MARKET SIZE 2035 | 145.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.21% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Gilead Sciences (US), Johnson & Johnson (US), Merck & Co. (US), Novartis (CH), Roche (CH), Sanofi (FR), Takeda Pharmaceutical (JP) |
| Segments Covered | Product Type, Application, End-use, Route of Administration |
| Key Market Opportunities | Advancements in personalized medicine and biologics drive growth in the US market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive competitive dynamics in the US market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US biopharmaceuticals market in 2024?**
A: The US biopharmaceuticals market was valued at $92.1 Billion in 2024.

**Q: What is the projected market valuation for the US biopharmaceuticals market by 2035?**
A: The market is projected to reach $145.0 Billion by 2035.

**Q: What is the expected CAGR for the US biopharmaceuticals market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 4.21%.

**Q: Which product type segment had the highest valuation in 2024?**
A: In 2024, the Monoclonal Antibodies segment had the highest valuation at $30.0 Billion.

**Q: What is the projected valuation for the Recombinant Proteins segment by 2035?**
A: The Recombinant Proteins segment is projected to reach $35.0 Billion by 2035.

**Q: Which application segment is expected to grow the most by 2035?**
A: The Oncology application segment is expected to grow the most, reaching $50.0 Billion by 2035.

**Q: What was the valuation of the Cellular Therapies segment in 2024?**
A: The Cellular Therapies segment was valued at $17.1 Billion in 2024.

**Q: Which end-use segment had the highest valuation in 2024?**
A: The Hospitals end-use segment had the highest valuation at $36.84 Billion in 2024.

**Q: What is the projected valuation for the Subcutaneous route of administration by 2035?**
A: The Subcutaneous route of administration is projected to reach $43.0 Billion by 2035.

**Q: Who are the key players in the US biopharmaceuticals market?**
A: Key players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck & Co., Novartis, Roche, Sanofi, and Takeda Pharmaceutical.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biopharmaceuticals-market-51388*